Abeona Therapeutics Announces Initial European Regulatory Approvals for Phase 1/2 Gene Therapy Clinical Studies for Patients With Sanfilippo Syndromes Type A (MPS IIIA) and Type B (MPS IIIB) Jan 11, 2016
Abeona Therapeutics Announces License for Next Generation AAV Delivery Vector for Fanconi Anemia and Rare Blood Disease Platform Oct 6, 2015
Abeona Therapeutics to Present at 2015 Rodman & Renshaw Annual Global Investment Conference Sep 3, 2015
